BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10501848)

  • 1. Function and dysfunction of CD4(+) T cells in the immune response to melanoma.
    Fischer WH; thor Straten P; Terheyden P; Becker JC
    Cancer Immunol Immunother; 1999 Oct; 48(7):363-70. PubMed ID: 10501848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costimulation via lymphocyte function-associated antigen 1 in the absence of CD28 ligation promotes anergy of naive CD4+ T cells.
    Ragazzo JL; Ozaki ME; Karlsson L; Peterson PA; Webb SR
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):241-6. PubMed ID: 11120881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
    Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
    Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity.
    Steinbrink K; Graulich E; Kubsch S; Knop J; Enk AH
    Blood; 2002 Apr; 99(7):2468-76. PubMed ID: 11895781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
    Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
    J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness.
    Chung JB; Wells AD; Adler S; Jacob A; Turka LA; Monroe JG
    J Immunol; 2003 Aug; 171(4):1758-67. PubMed ID: 12902475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction.
    Rouhani SJ; Eccles JD; Riccardi P; Peske JD; Tewalt EF; Cohen JN; Liblau R; Mäkinen T; Engelhard VH
    Nat Commun; 2015 Apr; 6():6771. PubMed ID: 25857745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma.
    Becker JC; Brabletz T; Czerny C; Termeer C; Bröcker EB
    Int Immunol; 1993 Dec; 5(12):1501-8. PubMed ID: 7906140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
    Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
    Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
    Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
    J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
    Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
    Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential susceptibility of naïve versus cloned CD4+ T cells to antigen-specific and MHC-restricted anergy induction.
    Liu QS; Zhang RH; Chu YW; Xiong SD
    Sheng Li Xue Bao; 2003 Dec; 55(6):633-40. PubMed ID: 14695478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.
    Varypataki EM; Hasler F; Waeckerle-Men Y; Vogel-Kindgen S; Høgset A; Kündig TM; Gander B; Halin C; Johansen P
    Front Immunol; 2019; 10():1548. PubMed ID: 31333674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
    Snook AE; Magee MS; Schulz S; Waldman SA
    Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.